Progenics Pharmaceuticals, Inc. (PGNX)

Oncology Corporate Profile

Stock Performance

5.4600
0.0800

HQ Location

777 Old Saw Mill River Road
Tarrytown, NY 10591

Company Description

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra__¢, an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, RELISTOR (methylnaltrexone bromide) Subcutaneous Injection for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.

Website: http://www.progenics.com

Brand Generic Indication
Relistor«•methylnaltrexone bromideRELISTOR (methylnaltrexone bromide) is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient. Use of RELISTOR beyond four months has not been studied.
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
PSMA ADCAntibody drug conjugateProstate cancerIII
1404PSMA Targeting imaging agent Prostate cancerII
1095PSMA Targeting imaging agent Prostate cancerI

Source


http://www.progenics.com

Recent News Headlines

Data from Phase 2 Study of Progenics’ PSMA-Targeted Imaging Agent 1404 Published in Journal of Nuclear Medicine

3/24/2017 12:03 pm

[GlobeNewswire] - NEW YORK, March 24, 2017-- Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced the publication of ...

Progenics reports 4Q loss

3/9/2017 12:04 pm

Progenics reports 4Q loss

3/9/2017 12:04 pm

Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2016 Financial Results and Business Update

3/9/2017 12:03 pm

[GlobeNewswire] - Registrational Phase 2 B Trial Topline Results for Ultra-Orphan Radiotherapeutic Candidate AZEDRA ® Expected First Quarter 2017 Independent DMC Recommended Continuation of Enrollment of Phase 3 Trial for ...

Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2016 Financial Results Call for March 9

2/23/2017 01:03 pm

[GlobeNewswire] - NEW YORK, Feb. 23, 2017-- Progenics Pharmaceuticals, Inc.,, an oncology company developing innovative medicines and other products for targeting and treating cancer, announced today that it will host a ...

Progenics Pharmaceuticals and Shutterfly to Join S&P SmallCap 600

2/15/2017 11:04 pm

[PR Newswire] - NEW YORK, Feb. 15, 2017 /PRNewswire/ -- Effective with this press release, S&P Dow Jones Indices will now reference index changes using an "effective at the open" date rather than an "after ...

Progenics Pharmaceuticals Announces Initiation of a Phase 1 Clinical Trial of its PSMA-Targeted Therapeutic Candidate 1095 For the Treatment of Metastatic Prostate Cancer

2/14/2017 12:00 pm

[GlobeNewswire] - NEW YORK, Feb. 14, 2017-- Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and other products for targeting and treating cancer, today announced that enrollment of an ...

Progenics Pharmaceuticals, Inc. to Participate in February Investor Conferences

2/8/2017 01:03 pm

[GlobeNewswire] - NEW YORK, Feb. 08, 2017-- Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and other technologies for targeting and treating cancer, today announced that Mark Baker, ...

Progenics Pharmaceuticals Announces Independent Committee's Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404

12/22/2016 09:03 pm

[at noodls] - December 22, 2016 NEW YORK, Dec. 22, 2016 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and other technologies for targeting and ...

Progenics Pharmaceuticals Announces Independent Committee’s Positive Recommendation for Continuation of Phase 3 Clinical Trial of SPECT/CT Imaging Agent 1404

12/22/2016 09:01 pm

[GlobeNewswire] - NEW YORK, Dec. 22, 2016-- Progenics Pharmaceuticals, Inc., an oncology company developing innovative medicines and other technologies for targeting and treating cancer, today announced that its independent ...